Kiniksa (KNSA) Form 144: Insider sale reported

Kiniksa Pharmaceuticals filed a Form 144 reporting proposed and recent sales of Class A Ordinary Shares.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals filed a Form 144 reporting proposed and recent sales of Class A Ordinary Shares. The report lists a broker payment for a cashless exercise on 04/28/2026 and discloses a prior sale of 7,278 shares by Sanj K Patel on 04/06/2026 for $363,949.

Insights

Securities Compliance Analyst

Routine Form 144 notice of intended and recent insider share sales.

Form 144s notify the SEC of proposed brokered sales by affiliates; this filing documents a cashless exercise route and a recent reported disposition of 7,278 shares for $363,949 on 04/06/2026. The filing is procedural and does not itself consummate a market transaction.

Timing and full proceeds treatment for the 04/28/2026 entry are defined as a broker payment for cashless exercise; subsequent transaction details and settlement will appear in trade reports or future Section 16 filings if executed.

Key Figures

Prior sale shares: 7,278 shares Proceeds reported: $363,949 Proposed sale date: 04/28/2026 +1 more

4 metrics

Prior sale shares 7,278 shares Sanj K Patel sale on 04/06/2026

Proceeds reported $363,949 Proceeds from the 7,278-share sale on 04/06/2026

Proposed sale date 04/28/2026 Broker payment for cashless exercise listed for Class A Ordinary Share

Form type Form 144 Notice of proposed sale by affiliate

Key Terms

cashless exercise, Form 144, Employee Stock Option Exercise

3 terms

cashless exercise financial

"Broker Payment for Cashless Exercise"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Employee Stock Option Exercise financial

"Employee Stock Option Exercise - See Remarks"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does KNSA's Form 144 report show?

It reports proposed and recent sales of Class A Ordinary Shares, including a cashless exercise entry dated 04/28/2026 and a prior sale on 04/06/2026.

How many shares did Sanj K Patel sell according to the filing?

The filing shows Sanj K Patel sold 7,278 shares on 04/06/2026, with reported proceeds of $363,949.

What is a "cashless exercise" listed in the Form 144?

A cashless exercise lets the option holder exercise options with a broker who pays the exercise cost and withholds shares to cover cost and taxes, per the filing's description.

Does this Form 144 mean shares were already sold on 04/28/2026?

The filing lists a proposed sale method dated 04/28/2026 described as a broker payment for a cashless exercise; execution and settlement are not confirmed in this notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/28/2026 - 04:49 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001532218
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	105 PICCADILLY, SECOND FLOOR LONDON UNITED KINGDOM W1J 7NJ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Patel Sanj K
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Share	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	344591	17780309.00	45900637	04/28/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Share	04/28/2026	Employee Stock Option Exercise - See Remarks	Kiniksa Pharmaceuticals, Ltd.			344591	04/28/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sanj K Patel 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	04/06/2026	7278	363949.00

144: Remarks and Signature

Remarks	The options on this filing may be sold over various dates.
Date of Notice	04/28/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	10/31/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Sanj K Patel
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)